Single User License
INR 134980
Site License
INR 269960
Corporate User License
INR 404940

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Cough-Pipeline Review, H1 2015

Cough-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Cough-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Cough-Pipeline Review, H1 2015', provides an overview of the Cough's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cough, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cough and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Cough

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Cough and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Cough products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Cough pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Cough

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Cough pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Cough Overview 9

Therapeutics Development 10

Pipeline Products for Cough-Overview 10

Pipeline Products for Cough-Comparative Analysis 11

Cough-Therapeutics under Development by Companies 12

Cough-Therapeutics under Investigation by Universities/Institutes 16

Cough-Pipeline Products Glance 17

Late Stage Products 17

Clinical Stage Products 18

Early Stage Products 19

Unknown Stage Products 20

Cough-Products under Development by Companies 21

Cough-Products under Investigation by Universities/Institutes 24

Cough-Companies Involved in Therapeutics Development 25

Afferent Pharmaceuticals, Inc. 25

Ahn-Gook Pharmaceutical Co., Ltd. 26

Alitair Pharmaceuticals, Inc. 27

Ario Pharma Ltd 28

AUS Bio Limited 29

Beijing Minhai Biotechnology Co., Ltd 30

Beijing Tiantan Biological Products Co., Ltd. 31

Bharat Biotech International Limited 32

Biological E. Limited 33

Daewoong Pharmaceutical Co., Ltd. 34

Daiichi Sankyo Company, Limited 35

DBV Technologies S.A. 36

GlaxoSmithKline plc 37

Glenmark Pharmaceuticals Ltd. 38

Green Cross Corporation 39

Hanmi Pharmaceuticals, Co. Ltd. 40

Hydra Biosciences, Inc. 41

Hyundai Pharmaceutical Co., Ltd. 42

Indian Immunologicals Limited 43

LG Life Sciences, Ltd. 44

NanoBio Corporation 45

Neos Therapeutics, Inc. 46

Novartis AG 47

Orbis Biosciences, Inc. 48

Panacea Biotec Limited 49

Sanofi 50

Sanofi Pasteur SA 51

Serum Institute of India Limited 52

Sinovac Biotech Ltd. 53

Synthetic Biologics, Inc. 54

Tesaro, Inc. 55

Vectura Group plc 56

Vernalis plc 57

Zydus Cadila Healthcare Limited 58

Cough-Therapeutics Assessment 59

Assessment by Monotherapy Products 59

Assessment by Combination Products 60

Assessment by Target 61

Assessment by Mechanism of Action 63

Assessment by Route of Administration 65

Assessment by Molecule Type 67

Drug Profiles 69

(ambroxol + levodropropizine)-Drug Profile 69

(chlorpheniramine maleate + codeine)-Drug Profile 70

(diphtheria + tetanus + pertussis (acelluar) + poliovirus (types 1, 2 ,3)) vaccine-Drug Profile 71

(diphtheria + tetanus + pertussis (acellular) + hepatitis B + poliomyelitis + haemophilus influenza [serogroup B]) vaccine-Drug Profile 72

AF-219-Drug Profile 74

AG-1321001-Drug Profile 76

AG-1321001-SY-Drug Profile 77

AGPPC-709-Drug Profile 78

benzonatate polacrilex-Drug Profile 79

CCP-01-Drug Profile 80

CCP-05-Drug Profile 81

CCP-06-Drug Profile 82

CCP-07-Drug Profile 83

CCP-08-Drug Profile 84

diphtheria + pertussis + tetanus + hepatitis [serotype B] + haemophilus influenza [serotype B] vaccine-Drug Profile 85

diphtheria + pertussis + tetanus vaccine-Drug Profile 86

diphtheria + pertussis + tetanus vaccine-Drug Profile 87

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 88

diphtheria + tetanus + pertussis (acellular) vaccine-Drug Profile 89

diphtheria + tetanus + pertussis (whole cell) + haemophilus influenzae [type B] + polio (pentavalent) vaccine-Drug Profile 90

diphtheria + tetanus + pertussis (whole cell) + hepatitis B + haemophilus influenzae [type B] + polio (hexavalent) vaccine-Drug Profile 91

diphtheria + tetanus + pertussis (whole-cell) + haemophilus influenzae [serotype B] vaccine-Drug Profile 92

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] (pentavalent) vaccine-Drug Profile 93

diphtheria + tetanus + pertussis (whole-cell) + hepatitis B + haemophilus influenzae [serotype B] vaccine-Drug Profile 94

diphtheria + tetanus + pertussis (whole-cell) + poliomyelitis + haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] (7-valent) vaccine-Drug Profile 95

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + haemophilus influenzae [type B] (pentavalent) vaccine-Drug Profile 96

diphtheria + tetanus+ pertussis (wholecell) + hepatitis [Type B] + poliomyelitis + haemophilus influenzae [type B] (hexavalent) vaccine-Drug Profile 97

diphtheria + tetanus+ pertussis vaccine-Drug Profile 98

diptheria + tetanus + pertussis (whole-cell) vaccine-Drug Profile 99

DTaP Vaccine-Drug Profile 100

DWJ-1340-Drug Profile 101

GC-3111A-Drug Profile 102

GRC-17536-Drug Profile 103

GSK-2339345-Drug Profile 104

guaifenesin ER-Drug Profile 105

HC-030031-Drug Profile 107

HOB-048-Drug Profile 109

LPCN-1087-Drug Profile 110

LPCN-1090-Drug Profile 111

MD-990-Drug Profile 112

pertussis (acellular) vaccine-Drug Profile 113

pertussis (acellular) vaccine-Drug Profile 114

pertussis (whole-cell) vaccine-Drug Profile 115

pertussis + hepatitis B vaccine-Drug Profile 116

pertussis vaccine-Drug Profile 117

pertussis vaccine-Drug Profile 118

pertussis vaccine-Drug Profile 119

pertussis vaccine-Drug Profile 120

pertussis vaccine-Drug Profile 121

Recombinant BCG-Pertussis Vaccine-Drug Profile 122

SCH-900978-Drug Profile 123

Small Molecule for Cough and Cold-Drug Profile 124

Small Molecule to Antagonize TRPA-1 for Pain And Respiratory Disorders-Drug Profile 125

SYN-005-Drug Profile 126

tetanus + diphtheria + pertussis (acellular) vaccine-Drug Profile 127

VN-0103-Drug Profile 128

VR-611-Drug Profile 129

XEND-0501-Drug Profile 130

Cough-Recent Pipeline Updates 132

Cough-Dormant Projects 138

Cough-Discontinued Products 142

Cough-Product Development Milestones 143

Featured News & Press Releases 143

Appendix 149

Methodology 149

Coverage 149

Secondary Research 149

Primary Research 149

Expert Panel Validation 149

Contact Us 149

Disclaimer 150

List of Tables

Number of Products under Development for Cough, H1 2015 14

Number of Products under Development for Cough-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 17

Number of Products under Development by Companies, H1 2015 (Contd..1) 18

Number of Products under Development by Companies, H1 2015 (Contd..2) 19

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Development, H1 2015 23

Comparative Analysis by Unknown Stage Development, H1 2015 24

Products under Development by Companies, H1 2015 25

Products under Development by Companies, H1 2015 (Contd..1) 26

Products under Development by Companies, H1 2015 (Contd..2) 27

Products under Investigation by Universities/Institutes, H1 2015 28

Cough-Pipeline by Afferent Pharmaceuticals, Inc., H1 2015 29

Cough-Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 30

Cough-Pipeline by Alitair Pharmaceuticals, Inc., H1 2015 31

Cough-Pipeline by Ario Pharma Ltd, H1 2015 32

Cough-Pipeline by AUS Bio Limited, H1 2015 33

Cough-Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2015 34

Cough-Pipeline by Beijing Tiantan Biological Products Co., Ltd., H1 2015 35

Cough-Pipeline by Bharat Biotech International Limited, H1 2015 36

Cough-Pipeline by Biological E. Limited, H1 2015 37

Cough-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 38

Cough-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 39

Cough-Pipeline by DBV Technologies S.A., H1 2015 40

Cough-Pipeline by GlaxoSmithKline plc, H1 2015 41

Cough-Pipeline by Glenmark Pharmaceuticals Ltd., H1 2015 42

Cough-Pipeline by Green Cross Corporation, H1 2015 43

Cough-Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 44

Cough-Pipeline by Hydra Biosciences, Inc., H1 2015 45

Cough-Pipeline by Hyundai Pharmaceutical Co., Ltd., H1 2015 46

Cough-Pipeline by Indian Immunologicals Limited, H1 2015 47

Cough-Pipeline by LG Life Sciences, Ltd., H1 2015 48

Cough-Pipeline by NanoBio Corporation, H1 2015 49

Cough-Pipeline by Neos Therapeutics, Inc., H1 2015 50

Cough-Pipeline by Novartis AG, H1 2015 51

Cough-Pipeline by Orbis Biosciences, Inc., H1 2015 52

Cough-Pipeline by Panacea Biotec Limited, H1 2015 53

Cough-Pipeline by Sanofi, H1 2015 54

Cough-Pipeline by Sanofi Pasteur SA, H1 2015 55

Cough-Pipeline by Serum Institute of India Limited, H1 2015 56

Cough-Pipeline by Sinovac Biotech Ltd., H1 2015 57

Cough-Pipeline by Synthetic Biologics, Inc., H1 2015 58

Cough-Pipeline by Tesaro, Inc., H1 2015 59

Cough-Pipeline by Vectura Group plc, H1 2015 60

Cough-Pipeline by Vernalis plc, H1 2015 61

Cough-Pipeline by Zydus Cadila Healthcare Limited, H1 2015 62

Assessment by Monotherapy Products, H1 2015 63

Assessment by Combination Products, H1 2015 64

Number of Products by Stage and Target, H1 2015 66

Number of Products by Stage and Mechanism of Action, H1 2015 68

Number of Products by Stage and Route of Administration, H1 2015 70

Number of Products by Stage and Molecule Type, H1 2015 72

Cough Therapeutics-Recent Pipeline Updates, H1 2015 136

Cough-Dormant Projects, H1 2015 142

Cough-Dormant Projects (Contd..1), H1 2015 143

Cough-Dormant Projects (Contd..2), H1 2015 144

Cough-Dormant Projects (Contd..3), H1 2015 145

Cough-Discontinued Products, H1 2015 146

List of Figures

Number of Products under Development for Cough, H1 2015 14

Number of Products under Development for Cough-Comparative Analysis, H1 2015 15

Number of Products under Development by Companies, H1 2015 16

Number of Products under Investigation by Universities/Institutes, H1 2015 20

Comparative Analysis by Late Stage Development, H1 2015 21

Comparative Analysis by Clinical Stage Development, H1 2015 22

Comparative Analysis by Early Stage Products, H1 2015 23

Assessment by Monotherapy Products, H1 2015 63

Assessment by Combination Products, H1 2015 64

Number of Products by Top 10 Targets, H1 2015 65

Number of Products by Stage and Top 10 Targets, H1 2015 66

Number of Products by Top 10 Mechanism of Actions, H1 2015 67

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 68

Number of Products by Top 10 Routes of Administration, H1 2015 69

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 70

Number of Products by Top 10 Molecule Types, H1 2015 71

Number of Products by Stage and Top 10 Molecule Types, H1 2015 72

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Afferent Pharmaceuticals, Inc.

Ahn-Gook Pharmaceutical Co., Ltd.

Alitair Pharmaceuticals, Inc.

Ario Pharma Ltd

AUS Bio Limited

Beijing Minhai Biotechnology Co., Ltd

Beijing Tiantan Biological Products Co., Ltd.

Bharat Biotech International Limited

Biological E. Limited

Daewoong Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Limited

DBV Technologies S.A.

GlaxoSmithKline plc

Glenmark Pharmaceuticals Ltd.

Green Cross Corporation

Hanmi Pharmaceuticals, Co. Ltd.

Hydra Biosciences, Inc.

Hyundai Pharmaceutical Co., Ltd.

Indian Immunologicals Limited

LG Life Sciences, Ltd.

NanoBio Corporation

Neos Therapeutics, Inc.

Novartis AG

Orbis Biosciences, Inc.

Panacea Biotec Limited

Sanofi

Sanofi Pasteur SA

Serum Institute of India Limited

Sinovac Biotech Ltd.

Synthetic Biologics, Inc.

Tesaro, Inc.

Vectura Group plc

Vernalis plc

Zydus Cadila Healthcare Limited

Cough Therapeutic Products under Development, Key Players in Cough Therapeutics, Cough Pipeline Overview, Cough Pipeline, Cough Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com